Dolutegravir is an integrase strand-transfer inhibitor used in combination therapy for the treatment of hiv infection. It is prescribed as part of antiretroviral regimens to suppress viral replication and improve immune function in adults and adolescents. The drug works by binding to the hiv integrase enzyme, preventing the virus from inserting its genetic material into the host cell's dna. This inhibition blocks the viral replication cycle at the stage of dna integration, reducing the production of new infectious particles. By limiting integration, Dolutegravir helps maintain lower viral loads and preserves cd4 cell counts, which are critical for immune health. The active ingredient therefore modulates the enzyme activity that drives viral genome incorporation, leading to sustained antiviral effect.

Dolutegravir is a synthetic antiretroviral medication classified as an integrase strand-transfer inhibitor. It is formulated for oral administration and is used as part of combination therapy to treat hiv infection. The drug functions by binding to the active site of the viral integrase enzyme. This binding prevents the integrase from joining viral dna fragments to the host cell genome. As a result the virus cannot complete its replication cycle and new infectious particles are not produced. Pharmacodynamically the compound exhibits a long half-life that allows for once-daily dosing in most patients. Its pharmacokinetic profile is characterized by extensive protein binding and minimal renal excretion. The overall pharmacological activity of Dolutegravir lies in its ability to suppress viral replication through inhibition of dna integration.

Dolutegravir may cause nausea in some patients. Headache is another frequently reported side effect. Fatigue can occur especially during the first weeks of treatment. Some individuals experience difficulty sleeping. Elevated liver enzymes have been observed in clinical studies. Skin rash can appear in a minority of users.

Dolutegravir is generally well tolerated in most patients. The most frequently reported side effects are headache and fatigue. Some individuals may experience nausea or mild abdominal discomfort. Insomnia and vivid dreams have also been observed. Elevated liver enzymes can occur but are usually mild and reversible. Rash and hypersensitivity reactions are possible but rare. These effects are typically transient and do not require discontinuation of therapy.